Niemelä Onni, Nivukoski Ulla, Bloigu Aini, Bloigu Risto, Aalto Mauri, Laatikainen Tiina
a Department of Laboratory Medicine and Medical Research Unit , Seinäjoki Central Hospital and University of Tampere , Seinäjoki , Finland.
b Medical Informatics and Statistics Research Group , University of Oulu , Oulu , Finland.
Scand J Clin Lab Invest. 2019 Feb-Apr;79(1-2):58-64. doi: 10.1080/00365513.2019.1571625. Epub 2019 Feb 5.
Low-risk thresholds for alcohol use differ across various national guidelines. To assess the novel WHO risk drinking levels in light of alcohol-sensitive common laboratory tests, we analysed biomarkers of liver status, inflammation and lipid profiles from a population-based survey of individuals classified to abstainers and different WHO risk drinking levels defined in terms of mean alcohol consumption per day. The study included 22,327 participants aged 25-74 years from the National FINRISK Study. Data on alcohol use, health status, diet, body weight and lifestyle (smoking, coffee consumption and physical activity) were recorded from structured interviews. Alcohol data from self-reports covering the past 12 months were used to categorize the participants into subgroups of abstainers and WHO risk drinking categories representing low, moderate, high and very high risk drinkers. Serum liver enzymes (GGT, ALT), C-reactive protein (CRP) and lipid profiles were measured using standard laboratory techniques. Alcohol risk category was roughly linearly related with the occurrence of elevated values for GGT, ALT and CRP. Alcohol drinking also significantly influenced the incidence of abnormalities in serum lipids. Significantly higher odds for abnormal GGT, ALT and altered lipid profiles remained in alcohol drinkers even after adjustment for age, waist circumference, physical inactivity, smoking and coffee consumption. A more systematic use of laboratory tests during treatment of individuals classified to WHO risk drinking categories may improve the assessment of alcohol-related health risks. Follow-ups of biomarker responses may also prove to be useful in health interventions aimed at reducing alcohol consumption.
不同国家指南中酒精使用的低风险阈值各不相同。为根据对酒精敏感的常见实验室检测评估世界卫生组织(WHO)新的饮酒风险水平,我们分析了基于人群的调查中肝脏状态、炎症和血脂谱的生物标志物,该调查对象为被分类为戒酒者以及根据每日平均酒精摄入量定义的不同WHO饮酒风险水平的个体。该研究纳入了来自芬兰全国风险研究(National FINRISK Study)的22327名年龄在25至74岁之间的参与者。通过结构化访谈记录了关于酒精使用、健康状况、饮食、体重和生活方式(吸烟、咖啡消费和体育活动)的数据。来自涵盖过去12个月自我报告的酒精数据被用于将参与者分类为戒酒者亚组以及代表低、中、高和非常高风险饮酒者的WHO饮酒风险类别亚组。使用标准实验室技术测量血清肝酶(γ-谷氨酰转移酶、谷丙转氨酶)、C反应蛋白(CRP)和血脂谱。酒精风险类别与γ-谷氨酰转移酶、谷丙转氨酶和CRP值升高的发生率大致呈线性相关。饮酒也显著影响血清脂质异常的发生率。即使在调整年龄、腰围、缺乏体育活动、吸烟和咖啡消费后,饮酒者中γ-谷氨酰转移酶、谷丙转氨酶异常和血脂谱改变的几率仍显著更高。在对被分类为WHO饮酒风险类别的个体进行治疗期间更系统地使用实验室检测可能会改善对酒精相关健康风险的评估。生物标志物反应的随访在旨在减少酒精消费的健康干预中也可能被证明是有用的。